Figure 1From: Personalized therapies in the cancer "omics" eraStepwise selection of antitumoral therapies based on individual oncogenic alterations. Analyses of oncogenic alterations in individual tumour samples using "omics" techniques should allow the identification of candidate targets for therapeutic intervention. Experimental preclinical validation of these targets is critical in order to proceed to the clinical testing of drugs that act on the selected targets.Back to article page